Evidence map›Paper›PMID 41390474›Full record

ArticleBMC research notes2025

Alarming colistin and carbapenem resistance in Klebsiella pneumoniae: molecular insights from Tehran hospitals, Iran.

Javad Yasbolaghi Sharahi, Hossein Goudarzi, Zohreh Ghalavand, Mehdi Goudarzi, Mohsen Javidi, Amirhossein Fayyazi, Monireh Kamali, Samaneh Babaei, Amirhossein Aghdaee, Ali Hashemi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. A Review ofInternational journal of microbiology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Javad Yasbolaghi SharahiDepartment of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0002-5183-6153
Hossein GoudarziDepartment of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-3052-6447
Zohreh GhalavandDepartment of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-1998-2716
Mehdi GoudarziDepartment of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0001-6720-9341
Mohsen JavidiDepartment of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0009-0009-9301-616X
Amirhossein FayyaziDepartment of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-0383-6722
Monireh KamaliCardiovascular Research Center, Rajaie Cardiovascular Institute, Tehran, Iran.ORCID https://orcid.org/0000-0002-8708-845X
Samaneh BabaeiNational Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Science, Tehran, Iran.
Amirhossein AghdaeeInfectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Ali HashemiDepartment of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ali.hashemi@sbmu.ac.ir.ORCID http://orcid.org/0000-0002-7258-5541

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAn alert has been issued regarding the widespread emergence of multidrug-resistant (MDR) and carbapenem-resistant Klebsiella pneumoniae (CRKP) in hospital settings. A total of 150 consecutive, non-duplicate K. pneumoniae isolates were obtained from patients admitted to tertiary care hospitals in Tehran between April 2023 and December 2024. These isolates were cultured from various clinical specimens, including sputum, urine, blood, wounds, bronchoalveolar lavage, and tracheal swabs. Antimicrobial susceptibility testing was performed using both disk diffusion and microdilution methods according to Clinical and Laboratory Standards Institute (CLSI) guidelines. Additionally, combined disk diffusion test (CDDT), modified carbapenem inactivation method (mCIM), and EDTA-modified carbapenem inactivation method (eCIM) tests were used to confirm the production of extended-spectrum β-lactamases (ESBLs), carbapenemases, and metallo-β-lactamases (MBLs), respectively. Biofilm production was assessed using the microtiter plate method with crystal violet staining. Molecular detection of ESBL genes (bla

resultsColistin showed the highest efficacy, with susceptibility rates of 83.3%. Notably, 25 isolates (16.7%) were colistin-resistant and 115 (76.7%) were carbapenem-resistant. Phenotypic analysis identified 87 (57.3%) isolates as ESBL producers, 93 (62%) as carbapenemase producers, and 79 (52.7%) as MBL producers. Biofilm production levels were categorized as strong (44 isolates, 29.3%), moderate (56, 37.3%), and weak (50, 33.3%). The spectrum of detected resistance genes included bla

Indexed as

Anti-Bacterial AgentsCarbapenemsColistinDrug Resistance, Multiple, BacterialKlebsiella InfectionsKlebsiella pneumoniaeBacterial Proteinsbeta-LactamasesBiofilmsHumansIranMaleMicrobial Sensitivity TestsAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesCarbapenemsColistinAntibiotic resistanceBiofilmbla NDMCarbapenemColistinESBLKlebsiella pneumoniaeMBL

Identifiers

PMID41390474
PMCPMC12817432

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.